Martin Babler

Insider Reports History

Entity
Individual
Location
C/O Alumis Inc., 280 East Grand Avenue, South San Francisco, CA
Signature
/s/ Sara Klein, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Martin Babler:

Stock Role Class Num Shares Value Price $ Report Date Ownership
ALUMIS INC. President, CEO and Chairman, Director Common Stock 90.8K $1.45M $16.00 Jul 1, 2024 By Trust
ALUMIS INC. President, CEO and Chairman, Director Stock Option (Right to Buy) 246K Jul 1, 2024 Direct
89bio, Inc. Director Stock Option (Right to Buy) 67.7K May 2, 2024 Direct
Neoleukin Therapeutics, Inc. Director Stock Option (Right to Buy) 25K Jun 8, 2023 Direct
Prelude Therapeutics Inc Director Director Stock Option (Right to Buy) 23.5K Jun 14, 2024 Direct
ALUMIS INC. President, CEO and Chairman, Director Class A Common Stock 0 Jul 1, 2024 By Trust

Insider Reports Filed by Martin Babler

Symbol Company Period Transactions Value $ Form Type Date Filed Role
ALMS ALUMIS INC. Jun 27, 2024 21 $0 4 Jul 1, 2024 President, CEO and Chairman, Director
ALMS ALUMIS INC. Jun 27, 2024 0 $0 3 Jun 27, 2024 President, CEO and Chairman, Director
PRLD Prelude Therapeutics Inc Jun 14, 2024 1 $0 4 Jun 18, 2024 Director
ETNB 89bio, Inc. May 2, 2024 1 $0 4 May 3, 2024 Director
ETNB 89bio, Inc. Apr 13, 2024 0 $0 3 Apr 23, 2024 Director
PRLD Prelude Therapeutics Inc Jun 16, 2023 1 $0 4 Jun 21, 2023 Director
NLTX Neoleukin Therapeutics, Inc. Jun 8, 2023 1 $0 4 Jun 9, 2023 Director
PRLD Prelude Therapeutics Inc Jun 17, 2022 1 $0 4 Jun 22, 2022 Director
NLTX Neoleukin Therapeutics, Inc. May 12, 2022 1 $0 4 May 16, 2022 Director
PRLD Prelude Therapeutics Inc Jul 19, 2021 1 $0 4 Jul 20, 2021 Director
PRLD Prelude Therapeutics Inc Jul 19, 2021 0 $0 3 Jul 20, 2021 Director
NLTX Neoleukin Therapeutics, Inc. May 11, 2021 1 $0 4 May 13, 2021 Director